Quick Answer
Petros Pharmaceuticals, Inc. reported Stockholders Equity of -$7.47 million for fiscal year 2024.
Petros Pharmaceuticals, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2024 | -$7.47M | -161.9% |
| 2023 | $12.07M | -27.7% |
| 2022 | $16.70M | -53.0% |
| 2021 | $35.54M | +103.5% |
| 2020 | $17.47M | +117.8% |
| 2019 | $8.02M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.37M | +8.1% | -24.3% |
| June 30, 2025 | $4.45M | -44.9% | +146.4% |
| March 31, 2025 | -$9.58M | -197.9% | -28.3% |
| December 31, 2024 | -$7.47M | -161.9% | -339.7% |
| September 30, 2024 | $3.12M | -55.1% | -61.4% |
| June 30, 2024 | $8.07M | -37.7% | -17.5% |
| March 31, 2024 | $9.79M | -36.6% | -18.9% |
| December 31, 2023 | $12.07M | -27.7% | +74.1% |
- Petros Pharmaceuticals, Inc. showed a decrease of -161.9% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2024 period, Petros Pharmaceuticals, Inc.’s stockholders equity has declined by 193.1% (from $8.02 million to -$7.47 million).
- The most recent figure is from Petros Pharmaceuticals, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: